
Monofer, an iron deficiency drug developed by Pharmacosmos, might have faced unfair conditions on the European market for years due to possible disparaging attempts by Vifor Pharma, according to the EU Commission, whose concerns have now led to a formal antitrust investigation into the matter.
In a press release, the Commission says it appears that the Swiss firm has attempted to stifle competition for its own blockbuster drug, Ferinject, an intravenous (IV) iron deficiency treatment, by spreading false information about Monofer’s safety, which is Vifor Pharma’s ”closest – and potentially only – competitor in Europe.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app